IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 1/2-ready biotech developing gene editing therapies for sickle cell and other diseases.
Industry: Health Care
Latest Trade: $15.72 0.00 (0.0%)
First Day Return: +8.8%
Return from IPO: -86.8%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 06/04/2021 |
Offer Price | $17.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 14.0 |
Deal Size ($mm) | $238 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 06/24/2021 |
Offer Price | $17.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 14.0 |
Deal Size ($mm) | $238 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Morgan Stanley |
BofA Securities |
more |
Company Data | |
---|---|
Headquarters | South San Francisco, CA, United States |
Founded | 2017 |
Employees | 27 |
Website graphitebio.com |